Analysis of a dozen published studies testing possible new uses for a Pfizer Inc. epilepsy drug found that reporting of the results was often fudged, indicating the medicine worked better than internal company documents showed. According to the... reviewreportingpfizerdrugstudiesfudged
To comment or read full article login. No account? Register free.